{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:35:27Z","timestamp":1782218127315,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009160).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>SoliMix (EudraCT: 2017\u2010003370\u201013) was a 26\u2010week, open\u2010label, multicentre study, where adults with T2D suboptimally controlled with BI plus one or two oral glucose\u2010lowering drugs and glycated haemoglobin (HbA1c) \u22657.5% to \u226410% were randomized to once\u2010daily iGlarLixi or twice\u2010daily BIAsp 30. Primary efficacy endpoints were non\u2010inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both primary efficacy endpoints were met in the LATAM region. After 26\u2009weeks, HbA1c was reduced by 1.8% with iGlarLixi and 1.4% with BIAsp 30, meeting non\u2010inferiority [least squares mean difference \u22120.47% (95% confidence interval: \u22120.82, \u22120.11);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001]. iGlarLixi was superior to BIAsp 30 for body weight change [least squares mean difference \u22121.27% (95% confidence interval: \u22122.41, \u22120.14);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.028]. iGlarLixi was also superior to BIAsp 30 for HbA1c reduction (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.010). A greater proportion of participants achieved HbA1c &lt;7% without weight gain and HbA1c &lt;7% without weight gain and without hypoglycaemia with iGlarLixi versus BIAsp 30. Incidence and rates of American Diabetes Association Level 1 and 2 hypoglycaemia were lower with iGlarLixi versus BIAsp 30.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once\u2010daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice\u2010daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15125","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:57:54Z","timestamp":1685494674000},"page":"2526-2534","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing therapy in people with suboptimally controlled basal insulin\u2010treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-8520","authenticated-orcid":false,"given":"Gustavo","family":"Frechtel","sequence":"first","affiliation":[{"name":"Departamento de Medicina Orientaci\u00f3n Nutrici\u00f3n, Facultad de Medicina, Universidad de Buenos Aires  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-5753","authenticated-orcid":false,"given":"Leobardo","family":"Sauque\u2010Reyna","sequence":"additional","affiliation":[{"name":"Instituto de Diabetes, Obesidad y Nutrici\u00f3n S.C., Cuernavaca, Mexico  Morelos Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-6355","authenticated-orcid":false,"given":"Ricardo","family":"Choza\u2010Romero","sequence":"additional","affiliation":[{"name":"Centro M\u00e9dico Ono  Aguascalientes Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Anguiano","sequence":"additional","affiliation":[{"name":"Medical Department Sanofi  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-8196","authenticated-orcid":false,"given":"Lydie","family":"Melas\u2010Melt","sequence":"additional","affiliation":[{"name":"Ividata Life Sciences  Levallois\u2010Perret France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8463-462X","authenticated-orcid":false,"given":"Mar\u00eda Elena","family":"Sa\u00f1udo\u2010Maury","sequence":"additional","affiliation":[{"name":"Medical Department Sanofi  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01341-9"},{"key":"e_1_2_9_3_1","first-page":"101","article-title":"Prevalencia de diabetes, obesidad y otros factores de riesgo cardiovascular. Estudio Venado Tuerto 3 (VT3)","volume":"11","author":"Corna R","year":"2021","journal-title":"Rev ALAD"},{"key":"e_1_2_9_4_1","unstructured":"Informe de Resultados de la Encuesta Nacional de Salud y Nutrici\u00f3n\u2014Continua 2021.2021https:\/\/ensanut.insp.mx\/encuestas\/ensanutcontinua2021\/informes.php"},{"key":"e_1_2_9_5_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas 10th edn. Brussels Belgium: 2021. Vol 10.https:\/\/www.diabetesatlas.orgAccessed Accessed 2 July 2023."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2020.10.001"},{"key":"e_1_2_9_7_1","unstructured":"World Obesity Federation Global Obesity Observatory.2022https:\/\/data.worldobesity.org\/. Accessed 2 July 2023"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_9_9_1","article-title":"ALAD Guidelines on the Diagnosis, Control and Treatment of Type 2 Diabetes Mellitus with Medicine Based on Evidence","author":"Association of Latin America Diabetes","year":"2019","journal-title":"Revista de la Asociacion Latinoamericana de Diabetes"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.21149\/10752"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12208"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01614-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108478"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14354"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S006"},{"issue":"8","key":"e_1_2_9_20_1","first-page":"2782","article-title":"Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi\u2010centric observational study","volume":"26","author":"Bilic\u2010Curcic I","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.05.020"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14518"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14148"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.585396"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00915.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12312"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP10079.OR"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:16:22Z","timestamp":1761862582000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/dom.15125"],"URL":"https:\/\/doi.org\/10.1111\/dom.15125","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"2023-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}